ABUS vs CDNS · P/E 5.4, rev $6.2M vs P/E 82, rev $5.30B
Arbutus Biopharma Corp (ABUS) versus Cadence Design Systems Inc (CDNS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Cadence Design Systems Inc (CDNS) is a software - application company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CDNS revenue for 2025-12-31 was $5.30B. Net income was $1.11B. Revenue was up 14.1% from 2024-12-31 to 2025-12-31. CDNS currently screens at market cap $88.27B and trailing P/E 82.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CDNS currently screens at market cap $88.27B and trailing P/E 82.0.
Not investment advice. Open the ABUS and CDNS stock pages for the full models.
Not investment advice.